tiprankstipranks
GT Biopharma’s Dr. Miller Assumes New Medical Director Role
Company Announcements

GT Biopharma’s Dr. Miller Assumes New Medical Director Role

Don't Miss Our Christmas Offers:

GT Biopharma ( (GTBP) ) just unveiled an update.

On September 16, 2024, Dr. Jeffrey Miller transitioned from his dual role as Consulting Chief Medical Officer and Chief Scientific Officer to become the Consulting Senior Medical Director for the same company. This change aligns with the University of Minnesota’s conflict of interest policies, as Dr. Miller is employed by the university, which is poised to conduct a Phase I clinical trial of the company’s new GTB-3650 compound.

For a thorough assessment of GTBP stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyGT Biopharma initiated with a Buy at Roth MKM
TheFlyGT Biopharma reports Q3 EPS ($1.53) vs. ($1.77) last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App